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Pooled Analysis of 6 and I2 month Smoking Abstinence Rates 
Smoking Cessation Aid 
(dose) 
N Abstinence rates at N Abstinence rates at 
6 months (%) 12 months (%) 
Nicotine Patch 
(21 mg/ day) 
Nicotine Chewing Gum (2 
mg) 
Nicotine Inhaler 
(4 mg) 
265 9.6 19.0 171 7.7 
7 8 
192 19.1 31.7 169 12.9 
5 9 
137 10.1 23.3 137 6.9 
6 6 
Bupropion (300 mglday) 
287 16.1 29.5 137 21.0 
5 6 
Behavioral Therapy 
678 45.0 
Active Placebo 
53.9 122 27.8 
2 
Active 
12.9 
23.9 
18.4 
32.8 
36.9 
1095-54 Radioactive Cigarettes and Corporate Strategy in Light 
of Evidence Derived From Declassified Tobacco 
Industry Documents 
Hrayr S. Karaaueuzian, James Whiting, Cedars-Sinai Medical Center, David G&en 
School of Medicine at UCLA, Los Angeles, CA 
Background: The presence of significant radioactivity in tobacco smoke still remains 
unacknowledged by the tobacco industry (TI). Declassified TI documents shed light oh 
this policy of silence. Methods: All major online soumes of TI documents made available 
by the Minnesota State Attorney General were searched using the terms polonium; 
radioactivity. A total of 56 TI documents and 26 academic publications were selected and 
analyzed. Results: Two sources of tobacco radioactivity have been identified: atmo- 
spheric fallout and soil rich in artificfal fertilizer containing radium, polonium 21OP0, and 
lead 210Pb. The documents show that the TI knew of the presence of significant radioac- 
tivity in tobacco smoke since the early 1950s and had at its disposal all the technical 
means and exoertise needed to measure radioactivity in tobacco leaves and smoke 
(matn & side streams). TI scientists reported 21OPo content of 0.5 pCi/cigarette (i.e., 
0.037 disinteoration oer sec. dos) with 12% of radioactivitv in the main stream and 32% 
in the side stream of the smoke. Since the average daily intake of 2lOPo from food and 
beverages averages 0.1 dps, smokers of one pack (20 cigarettes) a day may intake twice 
the 21OPo activity as nonsmokers. Postmortem findings at the btfurcation of the lower 
lobes of the lung of smokers who died from lung cancer had at least 3 times higher 
PlOPo/g of lung tissue than nonsmokers. Filtering proved ineffective I” 2lOPo removal 
(~0.1%). The concern over the potential hazards of the ionizing alpha particles of 210Po 
in the smoke led TI executives to ban publishing all internal research findings oh radioac- 
tivity. The TI executives found established methods of PO removal using acid treatment 
of tobacco leaves unacceptable because acid media converts ntcotlne base to nicotine 
salt with diminished ability to penetrate the brain causing loss of instant ‘nicotine kick,” 
the documents show. Conclusions: The declassified TI documents show that the industry 
had scientifically accurate knowledge of the presence of radioacbvity in tobacco smoke 
that might promote lung cancer. Adding a warning label oh cigarette packages that 
acknowledges the presence of radioactivity in tobacco smoke seems appropriate. 
1095-55 Additive Benefits of Pravastatin and Aspirin to 
Decrease Risks of Cardiovascular Disease: 
Randomized and Observational Comparisons of 
Secondary Prevention Trials and Their Meta-Analysis 
Charles H. Hennekens, Frank M. Sacks, Andrew Tonkin, Wouter Jukema, Robert P. 
Byington. Bertram Pin, Donald A. Berry, Scott M. Berry, Neville F. Ford, Andrew J. 
Walker, Kannan Natarajan, Chen Sheng-Lln, Frederick T. Fiedorek, Rene Belder, 
University of Miami School of Medicine, Miami, FL 
Background: In randomized trials of secondary prevention, pravastatin and aspirin 
reduce risks of cardiovascular disease (CVD). Pravastatin has a predominantly anti- 
atherogenic effect and aspirin ah immediate anti-platelet effect. Whether they have addi- 
tive clinical benefits has hot been demonstrated. 
Methods: In five randomized thals with pravastatin (40mg), comprising 73,900 patient- 
years of observation, aspirin was also prescribed. We tested whether pravastatin and 
aspihn have additive benefits in the two large trials (LIPID and CARE). We also per- 
formed meta-analyses of these two trials as well as three far smaller angiographic trials 
with clinical endpoktts. In all analyses multivariate models were used to adjust for a large 
number of CVD risk factors 
Results: Both indiwdual trials as well as all meta-analyses demonstrated similar additive 
benefits of pravastatin and aspirin. In meta-analysis the relative risk reductions (RRRs) 
for fatal or non-fatal myocardial infarction (Ml) were 31% for pravastatin plus aspirin ver- 
sus aspirin alone and 26% for pravastatin plus aspirin vemus pravastatin alone. For 
ischemic stroke the corresponding RRRs were 29% and 31%. For the combined ehd- 
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point of coronary heart disease death, non-fatal MI, coronary artery bypass graft, percu- 
taneous transluminal coronary angioplasty or ischemic stroke the RRRs were 24% and 
13%. All RRRs were statistically significant. 
Conclusions: In randomized and observational comparisons of secondary prevention tri- 
als and their meta-analyses there were additive benefits of pravastatin and aspirin in 
reducing risks of CVD. The more widespread and appropriate use of both pravastatin 
and aspirin in secondary prevention of CVD will avoid large numbers of premature 
deaths. 
109556 Do Lipoprotein Subclass Tests Increase Treatment 
Rates in High-Risk Patients? 
Ronald M. Krauss, Soma S. Nag, Shiva G. Sajjan, Thomas W. Weiss, John Brunzell, 
Jere P. Segrest, Leona E. Markson, Charles M. Alexander, Merck & Co.. Inc.. West 
Point, PA 
Background: Although considerable debate surrounds the utility of lipoprotein subclass 
tests versus (vs.) traditional lipid profiles in clinical practice, we are not aware of studies 
on the impact of the availability of lipoprotein subclass tests oh the process of care. 
Methods: A 6.month. randomized, prospective multi-center study evaluated the impact of 
lipoprotein subclass tests (Atherotech) on lipid treatment rates and treatment intensity 
(defined by statin dose and/or the use of combination lipid therapy). Physicians were ran- 
domized to Group A (lipoprotein subclass test results available initially and at 6-months) 
or Group B (traditional lipid values initially and subclass results available only at 6 
months). Untreated, high-risk patients (N=2576) with coronary head disease (CHD), dia- 
betes, or other CHD-risk equivalents were enrolled. There were no protocol-dictated 
requirements for lipid testing or treatment. 
Results: There were 09 Group A vs. 97 Group B physicians. 45% of patients were in 
Group A while 55% were in Group B. Mean age of patients was 64.4 +/- 12.9 years 
(range 16-97) with 47.4% male and 52.6% female. 87.0% were Caucasian, 7.9% were 
African-American, and 5.1% were other raceslethnicities. The results below have not yet 
been adjusted for any differences in baseline charactehstcs. The group provided kpid 
subclass results (A) had higher initial and 6.month lipid treatment rates vs B (initial: 
56.2% “s 51.1%. p=O.Ol; follow-up: A=71.4% vs. B=62.1%; p&0001). In the subgroup 
of patients with baseline LDL >= 100 (ie, needed treatment) who were ieitlally untreated, 
baseline lipid profile values did hot differ significantly; follow-up lipid treatment rates dlf- 
fered significantly (Group A, 44.8% vs. Group B, 33.9% p=O.O02). 
Conclusion: These initial findings suggest that availability of lipoprotein subclass tests in 
these high-risk patients increases treatment rates. The relationship between risk factors 
and baseline characterisbcs. and differences in treatment rates and intensity remain to 
be evaluated. 
1095-57 Adherence to Chronic Therapy Among Patients Treated 
for Hypertension, Dyslipidemia, or Both 
J. Sanford Schwartz. Trent McLaughlin, Deborah Griffts, Amy Arnold, Daniel Pettitt, NDC 
Health, Phoenix, AZ, Pfizer, Inc., New York, NY 
Background: Persistent utilization of medicine in patients wtth concurrent hypertension 
and dyslipidemia is particularly important due to their elevated risk for coronary events. 
The objective of this analysis was to quantify medication adherence for patients receiving 
both an antihypertensive drug (AHD) and lipid regulating therapy (LRD). 
Methods: Retrospective claims analysts using data from several managed care organiza- 
tions (Source: PHARMetrics Integrated Outcomes Database). Patients receiving 
AHD+LRD during 1999-2000 & having -> 1 year of history following the index agent were 
included. Medication possession ratios (MPR) were calculated at P-month intervals to 
assess adherence for the AHD, LRD and AHD + LRD combined. An MPR ~0.80 was 
considered to be indicative of appropriate adherence to medication. 
Results: 5,341 patients were included in the analysis. Over one-thtrd of the sample was 
non-adherent by the end of the second month. While patients tended to be more adher- 
ent with one medication, less than half were adherent with both by month 2, and less 
than one third were adherent to both after one year. 
MPR >0.80 
AHD 
LRD 
AHD + LRD 
Month 
l-2 
66.7% * 
47.7% * 
37.7% 
Month 
3-4 
58.8% ’ 
44.9% * 
35.5% 
Month 
5-6 
56.9% * 
43.6% * 
34.0% 
Month 
7-a 
56.0% * 
42.4% * 
33.2% 
Month 
9-10 
54.7% ’ 
42.0% * 
32.9% 
* p<O.O5 versus AHD+LRD 
Conclusions: The addition of a second aaent is associated with a sianificant reduction I” 
adequate medication adherence, such that less than one third of all patients remain on 
both AHD and LRD by the end of the first year. 
1095-58 Can Changing Referral Patterns Based on ACCIAHA’ 
Practice Guidelines for Coronary Angiography Be 
Measured? Validation of a Decision Analysis Model of 
Test Appropriateness in Coronary Artery Disease 
Patients 
D. Douqlas Miller, Edward J. Dougherty, Debra E. Messinger, Saint Louis University, St. 
Louis, MO 
Background: Despite reimbursement constraints, U.S. coronary angiogtaphy (oath.) 
rates continue to rise. We developed and validated a decision analysis model based oh 
1999 ACC/AHA Guidelines for Coronary Angiography to assess the appropriateness of 
elective cath. to a large Florida health plan (AvMED). 
Methods: A retrospective comparison of Cath. rates & appropriateness was performed 
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by random chart abstraction from 1999 (n=281 cases) and ZOOO(n=313 cases). Appropri- 
ate (class I & Ha) and Inappropriate (class Ilb & Ill) cath. was determined for 6 subsets of 
coronary artery disease(CAD): known/suspected CAD, nonspeciftc chest pain, unstable 
angina, post-revascularization ischemia, post-infarction( and CHF. The table summa- 
rizes overall model results from the 2 surveys. 
Results: An improvement was observed in appropriate cath. use from 1999 to 2000 for 
known/suspected CAD(from 35% to 19%; P<O.O5). An increase in inappropriate cath. 
occurred for unstable angina(from 0 to 26%; PcO.05). In both surveys, there was high 
inappropriate cath. in nonspecific chest pain (100% and 98%) and post-revascularization 
ischemia( 55% and 77%; P=NS), often before noninvasive ischemia testing. Model per- 
formance improved !n 2000, with only 1% of cases undiagnosed 8 unclassified. 
Conclusion: We conclude that this new decision analysis model. validated against ACCI 
AHA Practice Guidelines in Florida, can be prospectively exported to benchmark cath. 
Methods: Hosptial discharge data was obtained from the Washington State Dept of 
Health Comprehensive Hospital Abstract Reporting System and classified as CABG or 
PCI based on procedure codes from ICD-g-CM. Time series statistical analyses including 
age-sex adjustment and standardization to the year 2000 was performed to normalize 
case rates for changes in population demographics. 
Results: 
appropriateness in CAD pts. in other U.S. health systems. 
1999 
Cath. Appropriate 
(Class I or Ila) 
Cath. Inappropriate 
(Class Ilb or Ill) 
124 (44%) 
96 (34%) 
2000 
96 (31%) 
136 (43%) 
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1121-51 Is the incidence of Coronary Heart Disease Changing 
Over Time? 
Theresa J. Arciero, Steven J. Jacobsen, Robert L. Frye, Guy S. Aeeder, Susan A. 
Weston, Jill M. Killian. VBronique L. Roger, Mayo Clinic. Rochester, MN 
Background: Despite primary prevention efforts, the incidence of hospitalized myocar- 
dial infarction (Ml) changed kttle over the last 2 decades. Yet, it is unknown whether MI 
trends reflect overall coronary heart disease (CHD) trends. This study was designed to 
test the hypothesis that the incidence of CHD, es measured by other indicators, did not 
change over time 
Methods: Resources of the Rochester Epidemiology Project ascertained all CHD. 
including MI. unexpected sudden cardiac death (SCD), or significant coronary disease at 
angiography through community medical records using standardized epidemiological cri- 
teria. Secular trends were analyzed with Poisson regression. 
Results: From 1979 to 1998.5454 incident cases of CHD (Ml 1983, SCD 770, angiogra- 
phy 2701) occurred. The age-adjusted Incidence of CHD changed Over time (pxO.001) 
(Figure). In the first decade, it increased paralleling increased use of coronary angiogra- 
phy in the population. In the most recent decade, despite continued modest increase in 
use of angiography, the iwdence of all CHD declined in parallel to Ml and MIISCD. Over 
time, a larger proportion of persons with incident CHD were identified by positive angiog- 
raphy than MliSCD (p=<O.OOl). 
Conclusion: Over the last decade, characterized by increased surveillance, the tnci- 
dence of CHD declined suggesting benefits of prevention. Further, a sizable component 
of the CHD burden is identified by angiography, which is essential to more fully charac- 
terize CHD in the population. 
1121-52 Coronary Artery Bypass Graft Surgery Rates Are 
Decreasing: An Analysis of Trends in Surgery and 
Percutaneous Coronary Intervention Rates in 
Washington State From 1987-2001 
Matthew R. Ulrich, Douglas M. Brock, Andrew A Ziskind, University of Washington 
Seattle, WA 
Background: Advances I” percutaneous coronary intervention (PCI) and preventive 
strategies may decrease the need for coronary artery bypass graf surgery (CABG). This 
would have major implications for physician and hospital planning with regard to capaclty 
and the geographic distribution of cardiac services. 
Washington State CABG rates (eases/100,000 populationiyr) were stable until 1997. 
CABG rates then decreased from 105 in 1997 to 85 in 2001 (20% decrease). Total PCI 
rates increased from 69 in 1987 to 157 in 2001 (128% increase). CABG rates increased 
only for the subset of pts 75 and older. 
Conclusions: These data confirm that CABG rates are indeed decreasing in the general 
population. An increase in PCI rates appears to account for the majority of this decrease. 
1121-53 Improving Outcome of Percutaneous Coronary 
Intervention Through Application of Guidelines and 
Benchmarking: Reduction of Blood Transfusion as a 
Model 
Stanlev J. Chetcuti Paul M. Grossman, Debabrata Mukherjee, Eva M. Kline-Rogers, 
Cecelia Montoye, David Share, Michael J. O’Donnell, Ann Maxwell-Eward, William L. 
Meengs. John G. McGinnity, Kirit Patel, Mauro M. Moscucci. for the Blue Cross Blue 
Shield Michigan Cardiovascular Consortium (BMCP), University of Michigan Health 
System, Ann Arbor, Ml 
Background: The reported incidence of blood transfusion (TX) following PCI varies 
between 4 and 8%. No studies have assessed the potential Impact of TX guidelines on TX 
frequencies after PCI. Methods. Clinical procedural and outcome data on 25,144 consec- 
utive PCls were prospectively collected between July 1997 and September 2001 in a 
consortium of 8 hospitals in Michigan. Any TX event regardless of number of units trens- 
fused was recorded. A bedslde tool with guidelines for TX according to the American Col- 
lege of Physicians criteria was prepared and prospectively used in one of the 
participating institution. Additional interventions toward reduction of blood transfusion in 
this institution included continuous discussion with residents and other cardiologists of 
indication for blood TX. Results: In 1998, the TX rate was significantly higher in the index 
institution when compared with the consortium (pcO.001) (Table). Over the following 3 
years, there was a progressive decrease in the frequency of TX in this institution. In 2001, 
the TX rate in the same institution was the lowest within the consortium. This reduction in 
TX rates was not associated with a change in case mix, use of GP Ilb/llla receptor block- 
ers (>90% of cases in 2001) or with worse acute and long-term outcomes. Conclusions: 
TX is relatively common after PCI. The observed decrease in TX rates in this study 
through benchmarking and application of available guidelines suggests that TX might be 
a potential target for quality improvement efforts. 
Transfusion rates/year 
Transfusion 
Rates 
Year 1998 
Transfusion Transfusion Transfusion 
Rates Rates Rates 
Year 1999 Year 2000 Year 2001 
Index 
Hospital 
Consortium 
9.1’ 6.8 4.9 3.2” 
3.5 4.2 5.1 4.9 
* pcO.01 vs consortium; “p=O.O9 vs consortium; 
1121-58 Changing Sex Differences in Invasive Cardiac 
Procedure Rates Following Acute Myocardial Infarction 
Alan G. Wilson, John B. Kostis, Janet Lawrence-Nelson, Nora M. Cosgrove, Pearl D’Sa, 
for MIDAS, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 
Background: It is recognized that women receive fewer invasive cardiac procedures 
than men after acute myocardial infarction (AMI). However, changes in this gender gap 
Over time have not been well characterized. 
Methods Using a database of 193,805 patients who were hospitalized for AMI in New 
Jersey from 1986 to 1999, we examined rates of coronary angiography (CATH). angio- 
plasty (PTCA). and coronary artery bypass graft (CABG) performed within 90 days of 
their index admission. 
Results: In 1986 the unadiusted rate of CATH for women was 13.5 % cornDared to 
24.8% for men (a relative rate of 0.54); by 1999 CATH rates had increased to 43.8 % for 
women and 60 6 % for men ta relative rate of 0.72). However the absolute difference had 
widened from 11.3 % to 16.8 %. The adjusted odds ratio, controlling for age, AMI sever- 
ity, and year, for sex (men = 1) was 0.77 (95% Cl, 0.75-0.78). Stratifying the analysis by 
